An Opportunity to Advance Cannabis Science—DEA Rescheduling

IF 22.5 1区医学 Q1 PSYCHIATRY

JAMA Psychiatry Pub Date : 2025-02-05 DOI:10.1001/jamapsychiatry.2024.4691

Kevin P. Hill, Anshul V. Puli

引用次数: 0

Abstract

This Viewpoint discusses the regulatory and financial barriers to cannabis research, and the potential changes to these barriers if cannabis is reclassified as a Schedule III drug.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

JAMA Psychiatry PSYCHIATRY-

CiteScore

30.60

自引率

1.90%

发文量

233

期刊介绍： JAMA Psychiatry is a global, peer-reviewed journal catering to clinicians, scholars, and research scientists in psychiatry, mental health, behavioral science, and related fields. The Archives of Neurology & Psychiatry originated in 1919, splitting into two journals in 1959: Archives of Neurology and Archives of General Psychiatry. In 2013, these evolved into JAMA Neurology and JAMA Psychiatry, respectively. JAMA Psychiatry is affiliated with the JAMA Network, a group of peer-reviewed medical and specialty publications.